CRDL — Cardiol Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$123.09m
- CA$92.67m
Annual cashflow statement for Cardiol Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.6 | -31.6 | -30.9 | -28.1 | -36.7 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.91 | 7.79 | -2.26 | 3.25 | 12.2 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 8.32 | 0.077 | 5.75 | -0.546 | -0.932 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -9.19 | -23.6 | -27.2 | -25.2 | -25.1 |
| Capital Expenditures | -0.041 | -0.013 | -0.075 | -0.064 | -0.021 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.041 | -0.013 | -0.075 | -0.064 | -0.021 |
| Financing Cash Flow Items | -1.09 | -5.24 | 0 | — | -2.65 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.3 | 93.4 | -0.054 | -0.055 | 18.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.07 | 69.9 | -24.4 | -24.5 | -4.35 |